Literature DB >> 12019189

Involvement of liver carboxylesterases in the in vitro metabolism of lidocaine.

Stefan E H Alexson1, Margareta Diczfalusy, Magnus Halldin, Stellan Swedmark.   

Abstract

Although lidocaine has been used clinically for more than half a century, the metabolism has still not been fully elucidated. In the present study we have addressed the involvement of hydroxylations, deethylations, and ester hydrolysis in the metabolism of lidocaine to 2,6-xylidine. Using microsomes isolated from male rat liver, we found that lidocaine is mainly metabolized by deethylation to N-(N-ethylglycyl)-2,6-xylidine, and N-(N-ethylglycyl)-2,6-xylidine is mainly metabolized to N-glycyl-2,6-xylidine, also by deethylation. However, 2,6-xylidine can be formed both from lidocaine and N-(N-ethylglycyl)-2,6-xylidine, but not from N-glycyl-2,6-xylidine, in an NADPH-independent reaction, suggesting that the amido bond in these compounds can be directly hydrolyzed by esterases. To test this hypothesis, we incubated lidocaine, N-(N-ethylglycyl)-2,6-xylidine, and N-glycyl-2,6-xylidine with purified liver carboxylesterases. Rat liver microsomal carboxylesterase ES-10, but not carboxylesterase ES-4, hydrolyzed lidocaine and N-(N-ethylglycyl)-2,6-xylidine to 2,6-xylidine, identifying this esterase as a candidate enzyme in the metabolism of lidocaine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019189     DOI: 10.1124/dmd.30.6.643

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

Review 1.  Carboxylesterase inhibitors.

Authors:  M Jason Hatfield; Philip M Potter
Journal:  Expert Opin Ther Pat       Date:  2011-05-24       Impact factor: 6.674

2.  Lidocaïne test for easier and less time consuming assessment of liver function in several hepatic injury models.

Authors:  Dorra Ben Said; Ridha Ben Ali; Henda Ferchichi; Issam Salouage; Lobna Ouanes; Emna Gaïes; Sameh Trabelsi; Emna Kooli; Nadia Kourda; Jaouida Abdelmoula; Mohamed Lakhal; Anis Klouz
Journal:  Hepatol Int       Date:  2011-03-23       Impact factor: 6.047

3.  Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1.

Authors:  Sompop Bencharit; Carol C Edwards; Christopher L Morton; Escher L Howard-Williams; Peter Kuhn; Philip M Potter; Matthew R Redinbo
Journal:  J Mol Biol       Date:  2006-08-15       Impact factor: 5.469

4.  In Silico Design and Evaluation of Carboxylesterase Inhibitors.

Authors:  Shana V Stoddard; Xiaozhen Yu; Philip M Potter; Randy M Wadkins
Journal:  J Pest Sci (2004)       Date:  2010       Impact factor: 5.918

5.  Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.

Authors:  Latorya D Hicks; Janice L Hyatt; Shana Stoddard; Lyudmila Tsurkan; Carol C Edwards; Randy M Wadkins; Philip M Potter
Journal:  J Med Chem       Date:  2009-06-25       Impact factor: 7.446

6.  Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.

Authors:  M Jason Hatfield; Jingwen Chen; Ellie M Fratt; Liying Chi; John C Bollinger; Randall J Binder; John Bowling; Janice L Hyatt; Jerrod Scarborough; Cynthia Jeffries; Philip M Potter
Journal:  J Med Chem       Date:  2017-02-07       Impact factor: 8.039

7.  Esterase Activity and Intracellular Localization in Reconstructed Human Epidermal Cultured Skin Models.

Authors:  Yoshihiro Tokudome; Mishina Katayanagi; Fumie Hashimoto
Journal:  Ann Dermatol       Date:  2015-05-29       Impact factor: 1.444

8.  Carboxylesterase Activities and Protein Expression in Rabbit and Pig Ocular Tissues.

Authors:  Anam Hammid; John K Fallon; Toni Lassila; Giulia Salluce; Philip C Smith; Ari Tolonen; Achim Sauer; Arto Urtti; Paavo Honkakoski
Journal:  Mol Pharm       Date:  2021-02-17       Impact factor: 4.939

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.